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Abstract 
Protein kinase C(PKC)β2 is preferably overexpressed in the diabetic myocardium, 
which induces cardiomyocyte hypertrophy and contributes to diabetic cardiomyopathy, 
but the underlying mechanisms is are incompletely understood. Caveolae are critical in 
signal transduction of PKC isoforms in cardiomyocytes. Caveolin(Cav)-3, the 
cardiomyocyte-specific caveolar structural protein isoform, is decreased in the diabetic 
heart. The current study determined whether PKCβ2 activation affects caveolae and 
Cav-3 expression. Immunoprecipitation and immunofluorescence analysis revealed 
that high glucose(HG) increased the association and co-localization of PKCβ2 and 
Cav-3 in isolated cardiomyocytes. Disruption of caveolae by methyl-β-cyclodextrin or 
Cav-3 siRNA transfection prevented HG-induced PKCβ2 phosphorylation. Inhibition 
of PKCβ2 activation by compound CGP53353 or knockdown of PKCβ2 expression via 
siRNA attenuated the reductions of Cav-3 expression and Akt/eNOS phosphorylation 
in cardiomyocytes exposed to HG. LY333531 treatment (for a duration of 4 weeks) 
prevented excessive PKCβ2 activation and attenuated cardiac diastolic dysfunction in 
rats with streptozotocin-induced diabetes. LY333531 suppressed the decreased 
expression of myocardial nitric oxide(NO), Cav-3, p-Akt, and p-eNOS, and also 
mitigated the augmentation of O2-, nitrotyrosine, Cav-1, and iNOS expression. In 
conclusion, hyperglycemia-induced PKCβ2 activation requires caveolae, and is 
associated with reduced Cav-3 expression in the diabetic heart. Prevention of excessive 
PKCβ2 activation attenuated cardiac diastolic dysfunction by restoring Cav-3 
expression and subsequently rescuing Akt/eNOS/NO signaling. 
Key words: PKC-β2, caveolae, caveolin-3, diabetes  
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Introduction 
Cardiovascular disease is the leading cause of diabetes-related death (1). While most 
diabetic heart failure etiology concerns coronary disease associated with 
atherosclerosis, a diabetes-associated cardiomyopathy has been reported in humans (2) 
and animal models of Type 1 (3) and Type 2 diabetes (4). Numerous studies by our 
group(5, 6) and others (7, 8) suggest the involvement of excess expression or activation 
of protein kinase C (PKC) β2 in the development and progression of diabetic 
cardiomyopathy. Moreover, inhibition of PKCβ activation improves cardiac function in 
diabetic animals (9, 10). Despite these observations, the underlying mechanism by 
which PKCβ2 activation exerts deleterious effects in the diabetic myocardium remains 
unclear. 
 
PKCβ1 and PKCβ2 are two of classical isoforms (α, β, and γ) of PKC (11). Of the two 
isoforms, PKCβ2 is preferentially overexpressed in the myocardium of patients (12) or 
animals (13) with diabetes. PKCβ2 activation has been implicated in 
diabetes-associated abnormalities via inhibition of Akt-dependent endothelial nitric 
oxide (NO) synthase (eNOS) activity (14) and that restoration of Akt-eNOS-NO 
signaling has been shown to attenuate diabetic cardiomyopathy and myocardial 
dysfunction (15). Altered caveolae formation may potentially be the root cause of such 
inhibition. Caveolae, lipid rafts formed by small plasma membrane invaginations, serve 
as platforms modulating signal transduction pathways (e.g., PKC isoforms (16) via 
molecules docked with caveolin (Cav), a major constituent protein associated with 
caveolae. Of the three caveolin isoforms identified in mammalian caveolae, Cav-3 is 
mainly expressed in cardiac muscle, and is essential for proper formation of 
cardiomyocyte caveolae(17). Interestingly, in cardiomyocytes, eNOS localizes to 
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Cav-3 (18), permitting eNOS activation by cell surface receptors, and cellular surface 
NO release for intercellular signaling (18). Therefore, NO is an endogenous inhibitor of 
hypertrophic signaling (19), and Cav-3 is important for maintaining NO function. 
Additionally, Cav-3 has been demonstrated to inhibit growth signaling in the hearts of 
non-diabetic subjects (20). Thus, any alteration in Cav-3 expression in the diabetic 
condition may participate in the pathogenesis of diabetic cardiomyopathy, which is 
supported by findings that decreased cardiac Cav-3 expression is detected in rats with 
chronic streptozotocin (STZ)-induced diabetes (21, 22). In the present study, we 
hypothesize that PKCβ2 activation induced by hyperglycemia promotes caveolae 
dysfunction with associated signaling abnormality. Our data suggests that excessive 
PKCβ2 activation during diabetes reduces Cav-3 expression, with subsequent 
decreased Akt/eNOS signaling, which ultimately and negatively impact on cardiac 
remodeling and function. 
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RESEARCH DESIGN AND METHODS 
Induction of diabetes and drug treatment 
Male Sprague-Dawley rats (aged 8 weeks) weighing 260±10 g equilibrated to 
surroundings for three days before experiments. Diabetes was induced via single tail 
vein injection of STZ (60 mg/kg, Sigma, St. Louis, MO, USA) dissolved in citrate 
buffer (0.1 M, pH 4.5), while control rats were injected with an equal volume citrate 
buffer alone. One week after STZ injection, rats exhibiting hyperglycemia (blood 
glucose ≥16.7 mM) were considered diabetic, and were subjected to outlined 
experiments. One week after diabetes induction, rats were treated with vehicle or PKCβ 
inhibitor LY333531 (also named ruboxistaurin, a drug that has been approved by FDA 
for the prevention of vision loss in patients with diabetic retinopathy (23) by oral 
gavage for 4 weeks at dose  of 1 mg/kg/day (demonstrated to adequately inhibit PKCβ 
activation in rat heart and vasculature (24, 25)). This model was chosen based on our 
most recent study (26) and the study of others (27) showing that STZ-diabetic rats 
developed cardiac dysfunciton 35 days after STZ-injection, with concomitant 
cardiomyocytes hypertrophy and cardiac fibrosis formation(26) , two major features of 
diabetic cardiomyopathy. After 4 weeks treatment, cardiac functions were determined, 
the rats were then deeply anesthetized with sodium pentobarbital (65 mg/kg), and 
hearts were rapidly excised either for cardiomyocyte isolation or frozen in liquid 
nitrogen for later analysis. Subgroups of control and untreated diabetic rats were 
terminated at 8 weeks of STZ-induced diabetes and heart tissue samples were 
processed to analyze changes of cardiac PKCβ2 and Cav-3 at a relatively later phase of 
the disease. All experiments performed conformed to the Guide for the Care and Use of 
Laboratory Animals, published by the National Institutes of Health (NIH Publication 
No. 86-23, revised 1996) and were approved by the Institutional Animal Care and Use 
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Committee of Hong Kong University. 
 
Echocardiography. 
At the conclusion of 4 weeks treatments, transthoracic echocardiography was 
performed at experiment termination via a 17.5 MHz linear array transducer system 
(Vevo 770™, High Resolution Imaging System, Visual Sonics Inc., Canada) and left 
ventricular (LV) dimensions, LV diastolic and systolic function were assessed by 
M-mode and Doppler echocardiography as we previously described (26). LV internal 
dimensions at end systole (LVIDs) and diastole (LVIDd) were used to calculate 
fractional shorting (FS) by the following formula: FS(%) = 
(LVIDd-LVIDs)/LVIDd×100%. Left ventricular posterior wall dimensions at end 
diastole (LVPWd) and systole (LVPWs) were used to calculate fractional left 
ventricular posterior wall thickening (FLVPW) by the following formula: LVPW(%) = 
LVPWs-LVPWd/LVPWd×100%. The peak velocity of early (E) and late (A) diastolic 
filling were used to calculate the ratio of E and A (E/A). LV end-diastolic volume 
(LVVd) and end-systolic volume (LVVs) were used to calculate ejection fraction (EF) 
by the following formula: EF(%) = LVVd-LVVs/LVVd×100%. The heart rate (HR), 
systolic interventricular septal thickness (IVSs), diastolic interventricular septal 
thickness (IVSd), left ventricular isovolumic relaxation time (IVRT) and stroke volume 
(SV) were also monitored. All echocardiographically derived measures were obtained 
by averaging the readings of three consecutive beats. 
 
Preparation of isolated rat ventricular cardiomyocytes 
Calcium-tolerant cardiomyocytes were prepared from rat ventricles via a modified 
method as described (28). Cells isolated from a single rat heart were plated on 
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Matrigel-coated culture dishes and allowed to recover for 3 hours. Cultured ventricular 
cardiomyocytes were incubated in low glucose (5.5 mM), high glucose (25 mM), or 
mannitol/glucose (19.5 mMmannitol + 5.5 mM glucose) at 37 ℃in Medium 199  
(Gibco,  Grand Island, NY, USA)containing various treatments, and then snap frozen in 
liquid nitrogen for future analysis. LDH release (a measure of cell injury) in culture 
medium was detected via commercial LDH kit (Roche, Germany). 
 
Immunoprecipitation 
Isolated cardiomyocytes were homogenized in lysis buffer. 500 µg of cell extracts were 
subjected to immunoprecipitation with 2 µg of Cav-3 primary antibody in the presence 
of 20 µL protein A/G plus-agarose. After extensive PBS washes, 
theimmunoprecipitates were denatured with 1×SDS loading buffer, and subjected to 
analysis for PKCβ2 expression by Western blot as described below. 
 
Immunofluorescence 
Isolated cardiomyocytes were plated on Matrigel pre-coated glass coverslips, incubated 
either in low or high glucose in Medium 199 for 36 hours, and fixed in ice-cold acetone 
for 5 minutes. The fixed cells were blocked in PBST with 10% goat serum and 1% BSA 
for 30 minutes, and further incubated with a mixture of mouse against rat Cav-3 
antibody (1:50, Santa Cruz Biotechnology), and rabbit against rat PKCβ2 antibody 
(1:100, Santa Cruz Biotechnology) in 1% BSA in PBST in a humidified chamber for 1 
hour at room temperature. After three PBST washings, the cells were incubated for 1 
hour with a mixture of Alexa Fluor® 488 goat anti-mouse IgG and Alexa Fluor® 594 
goat anti-rabbit IgG (1:2000, Invitrogen, Carlsbad, CA). Cells were washed 3 times and 
prepared for confocal laser scanning microscopic imaging with mounting medium with 
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DAPI (Vector Laboratories, Inc., Burlingame, CA). 
 
PKCβ2 siRNA and Cav-3 siRNA studies in H9C2 cells 
Embryonic rat cardiac H9C2 cells were maintained in DMEM medium containing 10% 
fetal bovine serum in a humidified atmosphere (5% CO2) at 37 . Commercial PKCβ2 
siRNA and Cav-3 siRNA (Santa Cruz Biotechnology) were utilized for inhibition of 
both PKCβ2 and Cav-3 expression per manufacturer’s protocol. After transfection with 
control, PKCβ2 or Cav-3 siRNA, cells were incubated in either low or high glucose in 
DMEM medium for 36 hours, and snap frozen in liquid nitrogen. 
 
Determination of myocardial levels of NO, O2-, and nitrotyrosine 
Frozen heart tissues were pulverized separately with mortar and pestle in liquid 
nitrogen, homogenized in ice-cold PBS, and centrifuged at 3,000 g for 15 minutes at 
4°C for supernatant collection. The supernatant protein concentration was determined 
via a Lowry assay kit (Bio-Rad, CA, USA). Concentrations of nitrites (NO2−) and 
nitrates (NO3−), the stable end products of nitric oxide (NO), were determined by the 
Griess reaction as previously described(29). NO levels were expressed as nmol/µg 
protein. Myocardial O2- production was determined via lucigeninchemiluminescence 
method (30, 31). The supernatant samples were loaded with dark-adapted lucigenin (5 
µM), and read in 96-well microplates by luminometer (GloMax, Promega), with and 
without pretreatment with the NOS inhibitor L-NAME (100µM (15)) for 30 minutes at 
room temperature. Light emission, expressed as mean light units (MLU)/min/100 µg 
protein, was recorded for 5 minutes. Myocardial nitrotyrosine levels (µg/mg protein) in 
the collected supernatant were determined by chemiluminescence detection via the 
Nitrotyrosine Assay Kit per manufacturer's protocol (Millipore, USA).  
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Separation of cytosol and membrane fractions of heart tissues 
In order to characterize subcellular distributions of targeted proteins, cytosol and 
membrane fractions of cardiac tissue lysate were separated by ultracentrifugation 
described previously (5). Cytosol and membrane fractions were denatured by 5×SDS 
loading buffer, and subjected to analysis for PKCβ1 and PKCβ2 expression by Western 
blot as described below. 
 
Isolation of caveolin-rich fractions 
Caveolae were isolated by discontinuous sucrose gradient centrifugation as described 
previously(22). Each heart sample gradient was separated into 12 fractions. Fractions 
4-6 were considered the lipid raft fractions, and fractions 8-12 were considered the 
heavier fractions. Equal protein amounts were loaded for Western blot analysis. 
 
Western blot analysis 
Equal protein amounts from isolated cardiomyocytes, H9C2 cells, and rat heart 
homogenate were resolved by 7.5-12.5% SDS-PAGE and subsequently transferred to 
PVDF membrane for immunoblot analysis as described previously (32). 
 
Statistical analysis 
Densitometry was obtained by image analysis software (Bio-Rad). All values are 
presented as means ± S.E.M. Comparisons between multiple groups were made by 
one-way analysis of variance (ANOVA) followed by Tukey's test for multiple 
comparisons. Statistical analysis was performed by GraphPad Prism (GraphPad 
Software Inc., San Diego, CA, USA). P values less than 0.05 were considered 
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significant. 
 
RESULTS 
 
Expression and association of PKCβ2 and Cav-3 in cardiomyocytes isolated from 
diabetic rats 
We previously reported activation of the PKCβ2, but not PKCβ1, isoform in the diabetic 
heart (6). In the present study, we examined whether PKCβ2 activation was associated 
with abnormal Cav-3 expression, a muscle-specific marker of caveolae(17). Diabetes 
moderately increased PKCβ2 phosphorylation on thr-642 residue (data not shown), but 
the increase in phosphorylation of PKCβ2 on was most profound at serine residue 660, 
without influencing total PKCβ2, resulting in a markedly increased ratio of 
phosphorylated PKCβ2/total PKCβ2 (Figure 1A). Decreased Cav-3 expression was 
observed in cardiomyocytes isolated from 8-week diabetic rat hearts compared to 
age-matched control (Figure 1B). We next examined the relationship between Cav-3 
and PKCβ2 by immunoprecipitation experiments in isolated cardiomyocytes. While a 
small amount of PKCβ2 remained constitutively associated with Cav-3 during basal 
conditions, the diabetic condition increased its association with Cav-3 (Figure 1C). To 
confirm our findings, we utilized confocal immunofluorescence staining.  Limited 
PKCβ2 was present during basal conditions in association with Cav-3 in the cell 
membrane (indicated by scant yellow punctate staining of the cell periphery); 36 hours 
of high-glucose (HG) stimulation significantly increased regions of co-localization 
between PKCβ2 and Cav-3 compared to low-glucose (LG) stimulation (Figure 1D). 
 
Effect of high-glucose on expression and association of p-PKCβ2 and Cav-3 in 
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isolated cardiomyocytes over time 
High-glucose conditions significantly increased the ratio of p-PKCβ2/total PKCβ2 
(indicating PKCβ2 activation) in cardiomyocytes within 1 hour, for up to 48 hours 
(Figure 2A). Peak increase in the ratio of p-PKCβ2/total PKCβ2 occurred after 12 hours 
HG exposure. The osmotic control mannitol exerted no effects upon p-PKCβ2/total 
PKCβ2 and Cav-3 expression (data not shown). In contrast to the quick increase of 
p-PKCβ2/total PKCβ2 early as 1 hour after HG exposure, Cav-3 expression did not 
significantly increase until 6-12 hours after HG exposure, reduced to basal levels 
within 24 hours, and significantly decreased 36-48 hours after initial HG exposure 
(Figure 2B). Cardiomyocyte LDH release significantly increased 24 hours after HG 
exposure, with rising tendency continuing 36-48 hours after initial HG exposure 
(Figure 2C). 
 
Hyperglycemia-induced PKCβ2 activation involves caveolae and is associated 
with reduced Cav-3 expression 
We next investigate the interplay between PKCβ2 activation and caveolae (and Cav-3) 
under hyperglycemic conditions. Given that PKCβ1 activation induced by HG requires 
caveolae in primary mesangial cells (33), we determined whether caveolae are crucial 
in HG-induced PKCβ2 activation in isolated cardiomyocytes from non-diabetic rats. As 
shown in Figure 3A, phosphorylation of PKCβ2 induced by HG was prevented by either 
the selective PKCβ2 inhibitor CGP-53353 (CGP, 1µM, from Sigma-Aldrch, USA, IC50 
values are 0.41 µM and 3.8 µM respectively for PKCβ2 and PKCβ1) or 
methyl-β-cyclodextrin (CD, 50 µM, a disrupter of cholesterol-rich caveolae) (34). To 
determine whether Cav-3 is required for PKCβ2 activation, we subjected H9C2 cells 
treated with rat-specific Cav3-siRNA to both low- and high-glucose conditions.  
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siRNA-mediated reduction of Cav-3 expression by ~60% (Figure 3B) prevented 
augmented phosphorylation of PKCβ2 in HG conditions. No effects upon PKCβ2 
phosphorylation were observed in cells exposed to low glucose (LG) (Figure 3B). We 
also determined whether excessive PKCβ2 activation induced by HG is associated with 
reduced Cav-3 expression. Selective inhibition of PKCβ2 activation by CGP reversed 
the reduction of Cav-3 expression in primary cardiomyocytes exposed to HG (Figure 
3C). Similarly, in H9C2 cells, knockdown of PKCβ2 by siRNA reduced PKCβ2 
phosphorylation in cells incubated in LG and HG conditions (Figure 3D), and 
attenuated decreased Cav-3 expression in cells exposed to HG, with no impact upon 
Cav-3 expression in cells exposed to LG (Figure 3E). 
 
Hyperglycemia-induced activation of PKCβ2 is associated with 
caveolae-modulated Akt/eNOS signaling 
Next, we investigate the impact of PKCβ2 activation by HG, in the downstream 
signaling molecules Akt and eNOS, both modulated by caveolins(35). Cardiomyocytes 
incubated in HG exhibited decreased phosphorylation of Akt at Ser473 and eNOS at 
Ser1177, and these decreases were reversed by CGP treatment (Figures 4A and B). 
Caveolar disruption by CD further exaggerated HG-mediated reduction of Akt 
phosphorylation (Figure 4A), but did not further exacerbate HG-induced reduction of 
p-eNOS expression (Figure 4B). However, CGP mediated restoration of eNOS 
phosphorylation in HG-treated cardiomyocytes was abolished during concomitant CD 
treatment (Figure 4B). To confirm the relative effects of PKCβ2 and Cav-3 upon 
HG-mediated changes in p-AKT and p-eNOS, H9C2 cells were subject to both PKCβ2 
and Cav-3 knockdown by siRNA. PKCβ2 knockdown significantly increased the 
phosphorylation of Akt and eNOS in HG-treated cells, effects which were not observed 
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in LG-treated cells (Figure 4C). Knockdown of Cav-3 resulted in further reduced 
expression of both p-Akt and p-eNOS in both LG and HG-treated cells (Figure 4D). 
 
Inhibition of PKCβ2 activation by LY333531 attenuates cardiac caveolar 
dysfunction in diabetic rats 
To further investigate the role of PKCβ2 activation in diabetes-induced abnormalities, 
we treated STZ-induced diabetic rats with the PKCβ inhibitor LY333531 for 4 weeks. 
PKCβ2, but not PKCβ1, isoform was excessively activated in the diabetic heart, as 
demonstrated by increased membrane translocation of PKCβ2 but not PKCβ1, a 
phenomenon inhibited by LY333531 (Figure 5A). PKCβ2-inhibitor LY333531 
administration suppressed augmented whole-heart Cav-1 expression (Figure 5B), and 
prevented whole-heart decreased Cav-3 expression (Figure 5C). Caveolae fractions 
were isolated via discontinuous sucrose gradient centrifugation of whole cell lysates. 
Cav-1 was found predominantly in fractions 8-10, whereas Cav-3 was located within 
both lipid fractions (4-6) and heavier fractions (8-12). PKCβ2 was predominantly 
co-expressed within Cav-3-rich fractions (Figure 5D). Densitometric analysis of all 
fractions (1-12) demonstrated that PKCβ2-inhibitor LY333531 significantly reduced 
augmented Cav-1 and PKCβ2 expression, and suppressed decreased Cav-3 expression 
in diabetes (Figure 5E). 
 
Inhibition of PKCβ2 activation by LY333531 attenuates diastolic dysfunction in 
diabetic rats 
At the end of the treatment period, untreated diabetic rats had significantly elevated 
blood glucose and reduced body weight and heart weight as compared to control rats, 
which were not altered by LY333531 treatment (Table 1). However, the ratio of 
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heart-weight to body-weight, an indirect index of myocardial hypertrophy, in the 
untreated diabetic rats was significantly higher than that in the control rats, which was 
significantly attenuated by LY333531 treatment (Table 1). Further, the left ventricular 
cardiomyocyte cross-sectional areas as assessed in H&E stained cardiac sections 
(methodology available at Online appendix) in the untreated diabetic rats was 
significantly bigger than that in the control rats and was significantly attenuated by 
LY333531 treatment (online appendix Figure 1), showing that LY333531 can attenuate 
cardiomyocyte hypertrophy in diabetes. We further determined rat cardiac function via 
echocardiography. As shown in table 1, no significant change in fractional shorting 
(FS), fractional left ventricular posterior wall thickening (FLVPW), and ejection 
fraction (EF) was observed among all experimental groups (although non-significant 
decreased values were recorded in the untreated diabetic group. Such data suggests 
preserved systolic function at 4 5 weeks in diabetic rats as used in our model. However, 
diastolic dysfunction was manifested.  The heart rate (HR) and the ratio of peak 
velocity of early and late diastolic filling (E/A) was significantly decreased in diabetic 
rats as a consequence of significant reduction of E velocity and enhancement of A 
velocity that was concomitant with significant increase in left ventricular (LV) 
isovolumic relaxation time (IVRT) and reductions in LV end-diastolic volume (LVVd) 
and stroke volume (SV). Four weeks treatment with LY333531 restored the values of 
E/A, IVRT, LVVd and SV to levels that were comparable to that in the control rats but 
without significant effect upon HR.  
 
LY333531 ameliorated diabetic-induced derangements of myocardial NO, O2- 
and nitrotyrosine content, and reverted changes in cardiac Akt, eNOS and iNOS 
Diabetes is associated with decreased NO levels, and increased O2- and nitrotyrosine 
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production(15, 36), agents of oxidative and nitrative stress. To determine whether 
LY333531 conferred cardioprotection in part by reducing oxidative and nitrative stress 
in diabetes, the levels of NO, O2-, and nitrotyrosine in diabetic heart tissues were 
assessed. The diabetic condition significantly decreased NO levels (Figure 6A) and 
increased O2- (Figure 6B) and nitrotyrosine production (Figure 6C) in cardiac tissues. 
LY333531 suppressed all these derangements. Further studies revealed that the 
diabetes-induced augmented O2- levels could be blocked by the NOS inhibitor 
L-NAME (100 µM) (Figure 6B), suggesting a NOS-dependent mechanism for O2- 
accumulation. We next investigated related signaling molecules, including Akt, eNOS, 
and iNOS. The diabetic condition did not affect total cardiac Akt and eNOS expression, 
but significantly decreased p-Akt (Ser 473) and p-eNOS (Ser 1177) expression, both 
reversed by LY333531 (Figures 6D and E). Consistent with a recent study (37), our 
results demonstrated diabetes increased myocardial iNOS (an adverse marker 
mediating nitrative stress (24)), which was reversed by LY333531 (Figure 6F).
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DISCUSSION 
In the present study, we have demonstrated that hyperglycemia-induced cardiac PKCβ2 
activation requires caveolae. We provided evidence that excessive PKCβ2 activation is 
associated with reduced Cav-3 expression, contributing to abnormal Akt/eNOS 
signaling during hyperglycemia. Inhibition of excessive activation of PKCβ2 by 
compound LY333531 improves cardiac diastolic function, possibly via attenuation of 
caveolar dysfunction and rescuing Akt/eNOS/NO function in the diabetic heart. To our 
best knowledge, this is the first study examining the relationship between PKCβ2 and 
Cav-3 in cardiomyocytes subjected to hyperglycemic conditions. 
It is well-established that chronic hyperglycemia induces abnormal activation of PKC, 
which contributes to diabetic cardiovascular complications(38, 39). However, the PKC 
signaling pathway is complicated by numerous isoforms, each with varying cellular 
distribution and opposing function at times (40). The PKCβ2 isoform is most frequently 
implicated in diabetic cardiovascular complications (5-8). Our current study further 
confirmed that PKCβ2, but not PKCβ1, is excessively activated in the diabetic heart. 
Although the precise mechanisms by which hyperglycemia induces PKCβ2 activation 
in cardiomyocytes are not fully understood, evidence supports the vital role of caveolae 
(the specialized plasma membrane microdomains modulating signaling transduction 
pathways of molecules docked within them (17)) in hyperglycemia-induced PKCβ2 
activation. This is well supported by our immunoprecipitation and 
immunofluorescence studies demonstrating hyperglycemia increased the association 
and co-localization of PKCβ2 and Cav-3. Caveolar disruption by 
methyl-β-cyclodextrin(34) suppressed hyperglycemia-induced PKCβ2 activation in 
isolated cardiomyocytes. Cav-3 knockdown by siRNA prevented augmented PKCβ2 
phosphorylation in H9C2 cells exposed to high-glucose, suggesting that Cav-3 is 
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required specifically for hyperglycemia-induced PKCβ2 activation in cardiomyocytes.  
Cav-3 is the predominant cardiomyocyte caveolin isoform essential for caveolar 
function. In the current study, we demonstrated that cardiomyocyte Cav-3 expression 
increased 6-12 hours after HG exposure but reduced to basal levels within 24 hours and 
progressively further reduced to lower than basal levels after 36 to 48 hours of HG 
exposure. The initial increase in Cav-3 expression after HG exposure observed in our 
study is an acute response to the calorie surplus similar to that reported by other 
researchers(41). The significant reduction of Cav-3 expression in cardiomyocytes after 
prolonged HG exposure is consistent with our results from the intact rats which showed 
that Cav-3 expression was decreased in isolated cardiomyocytes from rats of 8 and 
5-week duration of diabetic condition. Loss of Cav-3 expression results in 
cardiomyopathy(42), and reduction in cardiac Cav3 protein expression is highly 
correlated with reduction in left ventricular fractional shortening in mice with 
constitutive overexpression of A1-adenosine receptor induced cardiac dilatation and 
dysfunction, and with makers of heart failure phenotype in humans (43). Our study 
results suggest excess PKCβ2 activation contributes towards attenuated Cav-3 
expression in the diabetic heart, as inhibition of PKCβ2 activation by CGP53353 or 
siRNA-mediated PKCβ2 expression knockdown prevented the decline of Cav-3 
expression in cells exposed to HG. LY333531 treatment ameliorated diabetic heart 
caveolae dysfunction. 
PKCβ2 activation likely exerts adverse effects in the diabetic heart via alteration of the 
Akt/eNOS signaling pathway, which is modulated by caveolins(35). Although Cav-1 
negatively regulates eNOS in cardiovascular tissues (44, 45), the co-localization of 
Cav-3 and eNOS may facilitate eNOS activation by both cell surface receptors and 
cellular surface NO release for intercellular signaling in cardiomyocytes(18). This is 
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supported by our findings that disruption of caveolae function by 
methyl-β-cyclodextrin or Cav-3 siRNA prevented Akt phosphorylation and suppressed 
eNOS phosphorylation in cardiomyocytes. Additionally, hyperglycemia decreased 
phosphorylated Akt and eNOS in both isolated cardiomyocytes and in diabetic heart 
tissues, leading to decreased myocardial NO levels, reduced Cav-3 levels, and 
increased Cav-1 cardiac levels. Inhibition of PKCβ2 activation suppressed or abrogated 
these alterations. Therefore, inhibition of PKCβ2 activation may rescue proper 
Akt/eNOS/NO signaling in the diabetic heart via caveolin regulation. 
Previous studies have demonstrated involvement of increased iNOS expression with 
cardiovascular abnormalities in STZ-induced diabetic rats (24, 46). Our study confirms 
increased iNOS cardiac content in diabetic rats, an adverse mediator of nitrative stress 
(24), and increased nitrotyrosine was also demonstrated in diabetic heart tissue. The 
NOS inhibitor L-NAME blocked diabetes-induced augmentation of O2- levels, 
indicating eNOS uncoupling, which is in line with a recent study in STZ-induced 
diabetic mice (47). Furthermore, treatment of diabetic rats with LY333531 inhibited 
cardiac iNOS expression and reduced both nitrotyrosine and O2- production. Diabetes 
is associated with decreased NO levels and increased O2-and nitrotyrosine production 
(15, 36), which are implicated with oxidative/nitrative stress and eNOS uncoupling. 
Our study provides direct evidence showing that inhibition of PKCβ2 activation can 
mitigate oxidative/nitrative stress and eNOS uncoupling. 
Initial left ventricular diastolic dysfunction, reduced contractility, and prolonged 
diastole are the hallmarks of diabetic cardiomyopathy (48, 49). In the present study, 
diabetes significantly reduced E/A ratio that was concomitant with significantly 
increased IVRT and decreased LVVd and SV, but did not alter fractional shorting (FS), 
fractional left ventricular posterior wall thickening (FLVPW) or ejection fraction (EF). 
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Such data indicates that myocardial diastolic (but not systolic) dysfunction occurs in 
45-week STZ-induced diabetic rats, which can be ameliorated by LY333531. Our 
findings are in general agreement with the findings of Mihm MJ et al (27) who 
conducted a series study in a similar STZ-diabetic rats and showed that diastolic 
dysfunction occurred early during the course of the disease which progressed to LV 
dilation reflected as increases in LVIDd and LVIDs with concomitant increase in LV 
luminal area and systolic dysfunction reflected as reduction in LV FS 35 days after 
STZ-injection and onward. It should be noted that the E/A ratio derived from the 
conventional Doppler echocardiography as used in our current study is not a 
load-independent parameter and may have inherent limitations, such as the peak E 
wave velocity can be highly dependent upon heart rate(27), while the heart rate in the 
diabetic rats was lower than that in the control group (Table 1). The newly developed 
Doppler tissue echocardiography (DTE) can acquire myocardial wall and mitral 
annular velocity online and the early diastolic annular velocity measured using DTE 
has been reported to be a preload independent index for evaluating LV diastolic 
function. A combination of DTE derived E’/A’ ratio and the mitral inflow patterns (E/A 
ratio) obtained by conventional Doppler echocardiography in future studies should help 
to provide better estimations of diastolic dysfunction. However, the significant 
reduction of E/A ratio as a consequence of significant reduction of E velocity and 
significant enhancement of A velocity in combination with concomitant increase in 
IVRT and reductions in LVVD and SV in the diabetic group could jointly suggest 
diastolic dysfunction in the current study. LY333531 treatment in diabetic rats did not 
affect heart rate but corrected all the above changes, suggesting the LY333531 
treatment prevented the development of diastolic dysfunction. Future functional study 
with cardiomyocytes isolated from various stages of diabetic rodents will help establish 
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the relative contribution of the slowing in cardiomyocyte relaxation time and left 
ventricular stiffness (due to fibrosis) to the development of  diastolic dysfunction. 
In summary, our study demonstrates that hyperglycemia-induced PKCβ2 activation is 
associated with caveolar dysfunction, and consequently deranged Akt/eNOS signaling 
(Figure 7). Inhibition of PKCβ2 activation attenuated cardiac diastolic dysfunction by 
restoring caveolin-3 expression and subsequently rescuing Akt/eNOS/NO signaling. 
PKCβ2 blockade may therefore represent a novel therapeutic avenue in the treatment of 
diabetic cardiomyopathy.  
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Table 1  
General characteristics and echocardiographic assessment of left ventricle dimensions 
and functions in rats 
 C D D+LY 
Blood glucose（mM） 6.26±0.53 28.24±4.64** 27.32±3.43** 
Body weight (g) 490.1±14.3 295.4±28.8* 371.1±17.4* 
Heart weight (g) 1.66±0.15 1.25±0.18* 1.31±0.16* 
Heart weight/bodyweight（mg/g） 3.39±0.07 4.23±0.06* 3.53±0.08# 
HR（bpm） 332±7.8 270±10.8* 286±9.2* 
LVIDs (mm) 4.75±0.43 4.68±0.41 4.74±0.49 
LVIDd (mm) 8.29±0.53 7.61±0.62 8.13±0.49 
FS (%) 42.70±4.13 38.50±5.42 41.53±3.84 
IVSs（mm） 2.23±0.16 2.28±0.07 2.27±0.13 
IVSd (mm) 1.72±0.05 1.75±0.05 1.73±0.06 
LVPWs (mm) 2.90±0.08 2.92±0.07 2.91±0.06 
LVPWd (mm) 1.85±0.06 1.91±0.09 1.87±0.08 
LVPW (%) 56.76±7.50 52.88±10.03 55.61±4.81 
LVVs (µL) 107.6±15.8 109.8±13.7 114.5±11.9 
LVVd (µL) 378.7±25.6 315.4±21.8* 380.4±19.7# 
EF (%) 71.6±4.7 65.2±5.7 69.9±3.9 
IVRT (ms) 21.75±1.25 27.83±1.80* 20.63±1.38# 
E Velocity (cm/s) 1340.9±44.6 1217.8±33.7* 1331.0±40.8# 
A Velocity (cm/s) 890.1±37.1 1023.4±34.7* 917.9±28.9# 
E/A 1.49±0.09 1.19±0.05* 1.45±0.085# 
SV (µL) 285.7±19.1 230.8±17.9* 279.4±20.8# 
Control or STZ-induced diabetic rats were either untreated or treated with PKCβ 
inhibitor LY333531 (LY, 1 mg/kg/day) by oral gavage for four weeks. HR, heart rate; 
LV, left ventricle; LVIDs, LV internal systolic diameter; LVIDd, LV internal diastolic 
diameter; FS, fractional shortening; IVSs, systolic interventricular septal thickness; 
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IVSd, diastolic interventricular septal thickness; LVPWs, LV systolic posterior wall 
thickness; LVPWd, LV diastolic posterior wall thickness; LVVs, LV end-systolic 
volume; LVVd, LV end-diastolic volume; EF, ejection fraction; IVRT, isovolumetric 
relaxation time; SV, stroke volume. All the results are expressed as means ± S.E.M., n = 
8, control (C), diabetes (D), LY333531 (LY). *P < 0.05, **P < 0.01 vs. C; #P < 0.05 vs. 
D. 
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Titles and legends to figures 
 
Figure 1.Expression of PKCβ2 and Cav-3 in cardiomyocytes isolated from control and 
STZ-induced diabetic rats (8-weeks). (A) Representative Western blot demonstrating 
p-PKCβ2 (Ser 660) and total-PKCβ2 expression. (B) Representative Western blot 
demonstrating Cav-3 expression with GAPDH as loading control. (C) Cell lysates 
containing equal amounts of total protein were subjected to immunoprecipitation with 
anti-Cav-3 antibody, and analyzed by immunoblot with PKCβ2 and Cav-3 antibody. All 
results expressed as means ± S.E.M., n=6-8 per group, *P<0.05 vs. control. (D) 
Confocal laser microscopic image of adult rat cardiomyocytes in response to high 
glucose. Isolated cardiomyocytes from non-diabetic rats were incubated with low or 
high glucose for 36 hours, and underwent standard immunofluorescent staining with 
PKCβ2 and Cav-3 antibodies (see Methods). 
 
Figure 2.Effects of high glucose upon p-PKCβ2 (Ser-660) and Cav-3 expression and 
LDH release in cultured cardiomyocytes over time. Representative Western blot of 
p-PKCβ2 (Ser 660) expression in comparison with (A) total-PKCβ2 and (B) Cav-3 
expression with GAPDH as loading control. (C) Effects of high glucose upon LDH 
release. *P<0.05 vs. control (time “0”) group. 
 
Figure 3.Expression of p-PKCβ2 and Cav-3 in cultured cardiomyocytes and H9C2 
cells following various treatments in low (5.5 mM) or high (25 mM) glucose conditions 
for 36 hours. (A) Representative Western blot demonstrating p-PKCβ2 (Ser 660) in 
comparison to total-PKCβ2 in cardiomyocytes exposed to high glucose in the presence 
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of a selective PKCβ2 inhibitor CGP-53353 (CGP, 1µM) or methyl-β-cyclodextrin (CD, 
10 µM). (B) Representative Western blot demonstrating p-PKCβ2 and Cav-3 
expression in H9C2 cells transfected with Cav-3 siRNA, exposed to low or high 
glucose. (C) Representative Western blot demonstrating Cav-3 expression in cultured 
cardiomyocytes exposed to high glucose in the presence of CGP (1µM). Representative 
Western blot demonstrating (D) p-PKCβ2, total PKCβ2 expression, and (D) Cav-3 
expression in H9C2 cells transfected with PKCβ2siRNA in low or high glucose 
conditions. GADPH served as loading control. All results are expressed as means ± 
S.E.M., n=7, *P<0.05 vs. all other groups, #P<0.05 vs. control-siRNA treated groups. 
 
Figure 4.Expression of p-Akt (Ser 473) and p-eNOS (Ser 1177) in cultured 
cardiomyocytes and H9C2 cells in various treatments in low (5.5 mM) or high glucose 
(25 mM) conditions for 36 hours. (A) Representative Western blot demonstrating p-Akt 
in comparison to total Akt, and (B) p-eNOS in comparison with total eNOS in 
cardiomyocytes exposed to high glucose in the presence of a selective PKCβ2 inhibitor 
CGP-53353 (CGP, 1µM), methyl-β-cyclodextrin (CD, 10 µM), or CGP+CD 
combination. Representative Western blot demonstrating p-Akt and p-eNOS 
expression in H9C2 cells transfected with (C) PKCβ2siRNA or (D) Cav-3 siRNA in low 
or high glucose conditions. GAPDH served as loading control. All results are expressed 
as means ± S.E.M., n=7, *P<0.05 vs. all other groups, #P<0.05 vs. control-siRNA 
treated groups. 
 
Figure 5.Effects of PKCβ inhibitor (LY333531) treatment upon subcellular 
distributions of PKCβ1 and PKCβ2, and expression levels of Cav-1 and Cav-3 in total 
heart preparations and various isolated cellular fractions. Control (C) or STZ-induced 
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diabetic rats were treated with PKCβ inhibitor LY333531 (1 mg/kg/day, D+LY) or 
control (D) by oral gavage for four weeks. (A) Representative Western blot 
demonstrating PKCβ1 and PKCβ2 protein expression. GAPDH and Na-K-ATPase 
served as loading controls in cytosol fractions or membrane fractions respectively. 
(Bottom graph) Membrane:cytosol ratio as indexes of PKCβ isoform translocation. 
Representative Western blot demonstrating (B) Cav-1 and (C) Cav-3 content in total 
heart preparations. (D) Sucrose gradient centrifugation isolated caveolae-enriched 
fractions. Aliquots containing equal amounts of protein or a volume equal to that of the 
fraction with the least detectable amount of protein for “protein-free” fractions (1 and 
2), and unfractionated samples (UF) were probed for Cav-1, Cav-3, and 
PKCβ2immunoreactivity. (E) Cav-1 and Cav-3 and PKCβ2 expression in all the 
fractions (1-12) were calculated by relative densitometric values, and expressed as 
percentage of control. All results expressed as means ± S.E.M., n=7, *P<0.05 vs. all 
other groups. 
 
Figure 6.Effects of PKCβ inhibitor (LY333531) treatment upon the levels of NO, O2-, 
nitrotyrosine, and protein expression of p-Akt, p-eNOS, and iNOS in diabetic 
myocardium. Control (C) or STZ-induced diabetic rats were treated with PKCβ 
inhibitor LY333531 (1 mg/kg/day, D+LY) or control (D) by oral gavage for four weeks. 
Effects of LY333531 upon (A) myocardial NO levels, (B) O2- levels in the absence and 
presence of L-NAME, and (C) nitrotyrosine levels; Representative Western blot of (D) 
p-Akt compared to total Akt, (E) p-eNOS compared to total eNOS, and (F) iNOS with 
GAPDH as loading control. All results expressed as means ± S.E.M., n=7, *P<0.05 vs. 
all other groups. 
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Figure 7.Schematic depicting hyperglycemia-induced PKCβ2 activation effects upon 
Cav-3-modulated Akt/eNOS signaling pathway.Cardiomyocytecaveolae are required 
for hyperglycemia-induced PKCβ2 activation (translocation from cytosol to caveolae 
membrane). Excessive PKCβ2activation decreased cav-3 expression, impairing the 
Akt/eNOS signaling pathway. Solid arrows depict stimulation, while transverse “T” 
shape indicates inhibition. 
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Abstract 
Hyperglycemia-induced p Protein kinase C (PKC) β2 activation is preferably 
overexpressed in the diabetic myocardium, which induces cardiomyocyte hypertrophy 
and contributes to diabetic cardiomyopathy, but the underlying mechanisms is are 
incompletely understood. Caveolae are critical in signal transduction of PKC isoforms 
in cardiomyocytes. Caveolin (Cav)-3 (Cav-3), the cardiomyocyte-specific caveolar 
structural protein isoform, is decreased in the diabetic heart. The current study 
determined whether PKCβ2 activation affects caveolae and Cav-3 expression. 
Immunoprecipitation and immunofluorescence analysis revealed that hyperglycemia 
high glucose (HG) increased the association and co-localization of PKCβ2 and Cav-3 
in isolated cardiomyocytes. Disruption of caveolae by methyl-β-cyclodextrin (CD) or 
Cav-3 siRNA transfection prevented hyperglycemia HG-induced PKCβ2 
phosphorylation. Inhibition of PKCβ2 activation by compound CGP53353 or 
knockdown of PKCβ2 expression via siRNA attenuated the reductions of Cav-3 
expression and Akt/eNOS phosphorylation in cardiomyocytes exposed to high-
glucose HG. Inhibition of PKCβ2 activation with LY333531 treatment (for a duration 
of 4 weeks) prevented excessive PKCβ2 activation and attenuated cardiac diastolic 
dysfunction in rats with streptozotocin-induced diabetes. LY333531 suppressed the 
decreased expression of myocardial nitric oxide (NO), Cav-3, p-Akt, and p-eNOS, 
and also mitigated the augmentation of O2
-
, nitrotyrosine, caveolin-1 Cav-1, and 
iNOS expression. In conclusion, hyperglycemia-induced PKCβ2 activation requires 
caveolae, and is associated with reduced Cav-3 expression in the diabetic heart. 
Inhibition Prevention of excessive PKCβ2 activation attenuated cardiac diastolic 
dysfunction by restoring Cav-3 expression and subsequently rescuing Akt/eNOS/NO 
signaling. 
Key words: PKC-β2, caveolae, caveolin-3, diabetes  
Page 34 of 75Diabetes
For Peer Review Only
 3
Introduction 
Cardiovascular disease is the leading cause of diabetes-related death (1). While most 
diabetic heart failure etiology concerns coronary disease associated with 
atherosclerosis, a diabetes-associated cardiomyopathy has been reported in humans 
(2) and animal models of Type 1 (3) and Type 2 diabetes (4). Numerous studies by our 
group(5, 6) and others (7, 8) suggest the involvement of excess expression or 
activation of protein kinase C (PKC) β2 in the development and progression of 
diabetic cardiomyopathy. Moreover, inhibition of PKCβ activation improves cardiac 
function in diabetic animals (9, 10). Despite these observations, the underlying 
mechanism by which PKCβ2 activation exerts deleterious effects in the diabetic 
myocardium remains unclear. 
 
PKCβ1 and PKCβ2 are two of classical isoforms (α, β, and γ) of PKC (11). Of the two 
isoforms, PKCβ2 is preferentially overexpressed in the myocardium of patients (12) or 
animals (13) with diabetes. PKCβ2 activation has been implicated in diabetes-
associated abnormalities via inhibition of Akt-dependent endothelial nitric oxide (NO) 
synthase (eNOS) activity (14) and that restoration of Akt-eNOS-NO signaling has 
been shown to attenuate diabetic cardiomyopathy and myocardial dysfunction (15). 
Altered caveolae formation may potentially be the root cause of such inhibition. 
Caveolae, lipid rafts formed by small plasma membrane invaginations, serve as 
platforms modulating signal transduction pathways (e.g., PKC isoforms (16) via 
molecules docked with caveolin (Cav), a major constituent protein associated with 
caveolae. Of the three caveolin isoforms identified in mammalian caveolae, Cav-3 is 
mainly expressed in cardiac muscle, and is essential for proper formation of 
cardiomyocyte caveolae(17). Interestingly, in cardiomyocytes, eNOS localizes to 
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Cav-3 (18), permitting eNOS activation by cell surface receptors, and cellular surface 
NO release for intercellular signaling (18). Therefore, NO is an endogenous inhibitor 
of hypertrophic signaling (19), and Cav-3 is important for maintaining NO function. 
Additionally, Cav-3 has been demonstrated to inhibit growth signaling in the hearts of 
non-diabetic subjects (20). Thus, any alteration in Cav-3 expression in the diabetic 
condition may participate in the pathogenesis of diabetic cardiomyopathy, which is 
supported by findings that decreased cardiac Cav-3 expression is detected in rats with 
chronic streptozotocin (STZ)-induced diabetes (21, 22). In the present study, we 
hypothesize that PKCβ2 activation induced by hyperglycemia promotes caveolae 
dysfunction with associated signaling abnormality. Our data suggests that excessive 
PKCβ2 activation during diabetes reduces Cav-3 expression, with subsequent 
decreased Akt/eNOS signaling, which ultimately and negatively impact on cardiac 
remodeling and function. 
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RESEARCH DESIGN AND METHODS 
Induction of diabetes and drug treatment 
Male Sprague-Dawley rats (aged 8 weeks) weighing between 260±10 g equilibrated 
to surroundings for three days before experiments. Diabetes was induced via single 
tail vein injection of STZ (60 mg/kg, Sigma, St. Louis, MO, USA) dissolved in citrate 
buffer (0.1 M, pH 4.5), while control rats were injected with an equal volume citrate 
buffer alone. One week after STZ injection, rats exhibiting hyperglycemia (blood 
glucose ≥16.7 mM) were considered diabetic, and were subjected to outlined 
experiments. One week after diabetes induction, rats were treated with vehicle or 
PKCβ inhibitor LY333531 (also named ruboxistaurin, a drug that has been approved 
by FDA for the prevention of vision loss in patients with diabetic retinopathy (23) by 
oral gavage for 4 weeks at dose  of 1 mg/kg/day (demonstrated to adequately inhibit 
PKCβ activation in rat heart and vasculature (24, 25)). This model was chosen based 
on our most recent study (26) and the study of others (27) showing that STZ-diabetic 
rats developed cardiac dysfunciton 35 days after STZ-injection, with concomitant 
cardiomyocytes hypertrophy and cardiac fibrosis formation(26) , two major features 
of diabetic cardiomyopathy. After 4 weeks treatment, Following determination of 
cardiac functions were determined, the rats were then deeply anesthetized with 
sodium pentobarbital (65 mg/kg), and hearts were rapidly excised either for 
cardiomyocyte isolation or frozen in liquid nitrogen for later analysis. Subgroups of 
control and untreated diabetic rats were terminated at 8 weeks of STZ-induced 
diabetes and heart tissue samples were processed to analyze changes of cardiac 
PKCβ2 and Cav-3 at a relatively later phase of the disease. All experiments performed 
conformed to the Guide for the Care and Use of Laboratory Animals, published by the 
National Institutes of Health (NIH Publication No. 86-23, revised 1996) and were 
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approved by the Institutional Animal Care and Use Committee of Hong Kong 
University. 
 
Echocardiography. 
At the conclusion of 4 weeks treatments, transthoracic echocardiography was 
performed at experiment termination via a 17.5 MHz linear array transducer system 
(Vevo 770™, High Resolution Imaging System, Visual Sonics Inc., Canada) and left 
ventricular (LV) dimensions, LV diastolic and systolic function were assessed by M-
mode and Doppler echocardiography as we previously described (26). Rats were 
lightly anesthetized by inhaled 2-3% isopentane for recording duration. Left 
ventricular LV internal dimensions at end systole (LVIDs) and diastole (LVIDd) were 
used to calculate fractional shorting (FS) by the following formula: FS(%) = (LVIDd-
LVIDs)/LVIDd×100%. Left ventricular posterior wall dimensions at end diastole 
(LVPWd) and systole (LVPWs) were used to calculate fractional left ventricular 
posterior wall thickening (FLVPW) by the following formula: LVPW(%) = LVPWs-
LVPWd/LVPWd×100%. The peak velocity of early (E) and late (A) diastolic filling 
were used to calculate the ratio of E and A (E/A). LV end-diastolic volume (LVVd) 
and end-systolic volume (LVVs) were used to calculate ejection fraction (EF) by the 
following formula: EF(%) = LVVd-LVVs/LVVd×100%. The heart rate (HR), systolic 
interventricular septal thickness (IVSs), diastolic interventricular septal thickness 
(IVSd), left ventricular isovolumic relaxation time (IVRT) and stroke volume (SV) 
were also monitored. All echocardiographically derived measures were obtained by 
averaging the readings of three consecutive beats. 
 
Preparation of isolated rat ventricular cardiomyocytes 
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Calcium-tolerant cardiomyocytes were prepared from rat ventricles via a modified 
method as described (28). Cells isolated from a single rat heart were plated on 
Matrigel-coated culture dishes and allowed to recover for 3 hours. Cultured 
ventricular cardiomyocytes cells were incubated in low glucose (5.5 mM), high 
glucose (25 mM), or mannitol/glucose (19.5 mMmannitol + 5.5 mM glucose) at 37 ℃
in Medium 199  (Gibco,  Grand Island, NY, USA)containing various treatments, and 
then snap frozen in liquid nitrogen for future analysis. LDH release (a measure of cell 
injury) in culture medium was detected via commercial LDH kit (Roche, Germany). 
 
Immunoprecipitation 
Isolated cardiomyocytes were homogenized in lysis buffer. 500 µg of cell extracts 
were subjected to immunoprecipitation with 2 µg of Cav-3 primary antibody in the 
presence of 20 µL protein A/G plus-agarose. After extensive PBS washes, 
theimmunoprecipitates were denatured with 1×SDS loading buffer, and subjected to 
analysis for PKCβ2 expression by Western blot as described below. 
 
Immunofluorescence 
Isolated cardiomyocytes were plated on Matrigel pre-coated glass coverslips, 
incubated either in low or high glucose in Medium 199 for 36 hours, and fixed in ice-
cold acetone for 5 minutes. The fixed cells were blocked in PBST with 10% goat 
serum and 1% BSA for 30 minutes, and further incubated with a mixture of mouse 
against rat Cav-3 antibody (1:50, Santa Cruz Biotechnology), and rabbit against rat 
PKCβ2 antibody (1:100, Santa Cruz Biotechnology) in 1% BSA in PBST in a 
humidified chamber for 1 hour at room temperature. After three PBST washings, the 
cells were incubated for 1 hour with a mixture of Alexa Fluor
®
 488 goat anti-mouse 
Page 39 of 75 Diabetes
For Peer Review Only
 8
IgG and Alexa Fluor
®
 594 goat anti-rabbit IgG (1:2000, Invitrogen, Carlsbad, CA). 
Cells were washed 3 times and prepared for confocal laser scanning microscopic 
imaging with mounting medium with DAPI (Vector Laboratories, Inc., Burlingame, 
CA). 
 
PKCβ2 siRNA and Cav-3 siRNA studies in H9C2 cells 
Embryonic rat cardiac H9C2 cells were maintained in DMEM medium containing 
10% fetal bovine serum in a humidified atmosphere (5% CO2) at 37 . Commercial 
PKCβ2 siRNA and Cav-3 siRNA (Santa Cruz Biotechnology) were utilized for 
inhibition of both PKCβ2 and Cav-3 expression per manufacturer’s protocol. After 
transfection with control, PKCβ2 or Cav-3 siRNA, cells were incubated in either low 
or high glucose in DMEM medium for 36 hours, and snap frozen in liquid nitrogen. 
 
Determination of myocardial levels of NO, O2
-
, and nitrotyrosine 
Frozen heart tissues were pulverized separately with mortar and pestle in liquid 
nitrogen, homogenized in ice-cold PBS, and centrifuged at 3,000 g for 15 minutes at 
4°C for supernatant collection. The supernatant protein concentration was determined 
via a Lowry assay kit (Bio-Rad, CA, USA). Concentrations of nitrites (NO2
−
) and 
nitrates (NO3
−
), the stable end products of nitric oxide (NO), were determined by the 
Griess reaction as previously described(29). NO levels were expressed as nmol/µg 
protein. Myocardial O2
- 
production was determined via lucigeninchemiluminescence 
method (30, 31). The supernatant samples were loaded with dark-adapted lucigenin (5 
µM), and read in 96-well microplates by luminometer (GloMax, Promega), with and 
without pretreatment with the NOS inhibitor L-NAME (100µM (15)) for 30 minutes 
at room temperature. Light emission, expressed as mean light units (MLU)/min/100 
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µg protein, was recorded for 5 minutes. Myocardial nitrotyrosine levels (µg/mg 
protein) in the collected supernatant were determined by chemiluminescence 
detection via the Nitrotyrosine Assay Kit per manufacturer's protocol (Millipore, 
USA).  
 
Separation of cytosol and membrane fractions of heart tissues 
In order to characterize subcellular distributions of targeted proteins, cytosol and 
membrane fractions of cardiac tissue lysate were separated by ultracentrifugation 
described previously (5). Cytosol and membrane fractions were denatured by 5×SDS 
loading buffer, and subjected to analysis for PKCβ1 and PKCβ2 expression by Western 
blot as described below. 
 
Isolation of caveolin-rich fractions 
Caveolae were isolated by discontinuous sucrose gradient centrifugation as described 
previously(22). Each heart sample gradient was separated into 12 fractions. Fractions 
4-6 were considered the lipid raft fractions, and fractions 8-12 were considered the 
heavier fractions. Equal protein amounts were loaded for Western blot analysis. 
 
Western blot analysis 
Equal protein amounts from isolated cardiomyocytes, H9C2 cells, and rat heart 
homogenate were resolved by 7.5-12.5% SDS-PAGE and subsequently transferred to 
PVDF membrane for immunoblot analysis as described previously (32). 
 
Statistical analysis 
Densitometry was obtained by image analysis software (Bio-Rad). All values are 
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presented as means ± S.E.M. Comparisons between multiple groups were made by 
one-way analysis of variance (ANOVA) followed by Tukey's test for multiple 
comparisons. Statistical analysis was performed by GraphPad Prism (GraphPad 
Software Inc., San Diego, CA, USA). P values less than 0.05 were considered 
significant. 
 
RESULTS 
 
Expression and association of PKCβ2 and Cav-3 in cardiomyocytes isolated from 
diabetic rats 
We previously reported activation of the PKCβ2, but not PKCβ1, isoform in the 
diabetic heart (6). In the present study, we examined whether PKCβ2 activation was 
associated with abnormal Cav-3 expression, a muscle-specific marker of 
caveolae(17). Diabetes moderately increased PKCβ2 phosphorylation on thr-642 
residue (data not shown), but the increase in increased phosphorylation of PKCβ2 on 
was most profound at serine residue 660, without influencing total PKCβ2, resulting 
in a markedly increased ratio of phosphorylated PKCβ2/total PKCβ2 (Figure 1A and 
B). Decreased Cav-3 expression was observed in cardiomyocytes isolated from 8-
week diabetic rat hearts compared to age-matched control (Figure 1B). We next 
examined the relationship between Cav-3 and PKCβ2 by immunoprecipitation 
experiments in isolated cardiomyocytes. While a small amount of PKCβ2 remained 
constitutively associated with Cav-3 during basal conditions, the diabetic condition 
increased both translocation of PKCβ2, and its association with Cav-3 (Figure 1C). To 
confirm our findings, we utilized confocal immunofluorescence staining.  Limited 
PKCβ2 was present during basal conditions in association with Cav-3 in the cell 
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membrane (indicated by scant yellow punctate staining of the cell periphery); 36 
hours of high-glucose (HG) stimulation significantly increased regions of co-
localization between PKCβ2 and Cav-3 compared to low-glucose (LG) stimulation 
(Figure 1D). 
 
Effect of high-glucose on expression and association of p-PKCβ2 and Cav-3 in 
isolated cardiomyocytes over time 
High-glucose conditions significantly increased p-PKCβ2 expression the ratio of p-
PKCβ2/total PKCβ2 (indicating PKCβ2 activation) in cardiomyocytes within 1 hour, 
for up to 48 hours (Figure 2A). Peak increase in p-PKCβ2 expression the ratio of p-
PKCβ2/total PKCβ2 occurred after 12 hours HG exposure. The osmotic control 
mannitol exerted no effects upon p-PKCβ2/total PKCβ2 p-PKCβ2 and Cav-3 
expression (data not shown). In contrast to the quick increase of p-PKCβ2/total PKCβ2 
p-PKCβ2 expressionas early as 1 hour after HG exposure, Cav-3 expression did not 
significantly increase until 6-12 hours after HG exposure, reduced to basal levels 
within 24 hours, and significantly decreased 36-48 hours after initial HG exposure 
(Figure 2B). Cardiomyocyte LDH release significantly increased 24 hours after HG 
exposure, with rising tendency continuing 36-48 hours after initial HG exposure 
(Figure 2C). 
 
Hyperglycemia-induced PKCβ2 activation involves caveolae and is associated 
with reduced Cav-3 expression 
We next investigate the interplay between PKCβ2 activation and caveolae (and Cav-3) 
under hyperglycemic conditions. Given that PKCβ1 activation induced by HG 
requires caveolae in primary mesangial cells (33), we determined whether caveolae 
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are crucial in HG-induced PKCβ2 activation in isolated cardiomyocytes from non-
diabetic rats. As shown in Figure 3A, phosphorylation of PKCβ2 induced by HG was 
prevented by either the selective PKCβ2 inhibitor CGP-53353 (CGP, 1µM, from 
Sigma-Aldrch, USA, IC50 values are 0.41 µM and 3.8 µM respectively for PKCβ2 
and PKCβ1) or methyl-β-cyclodextrin (CD, 50 µM, a disrupter of cholesterol-rich 
caveolae) (34). To determine whether Cav-3 is required for PKCβ2 activation, we 
subjected H9C2 cells treated with rat-specific Cav3-siRNA to both low- and high-
glucose conditions.  siRNA-mediated reduction of Cav-3 expression by ~60% (Figure 
3B) prevented augmented phosphorylation of PKCβ2 in HG conditions. No effects 
upon PKCβ2 phosphorylation were observed in cells exposed to normal low glucose 
(LG) (Figure 3B). We also determined whether excessive PKCβ2 activation induced 
by HG is associated with reduced Cav-3 expression. Selective inhibition of PKCβ2 
activation by CGP reversed the reduction of Cav-3 expression in primary 
cardiomyocytes exposed to HG (Figure 3C). Similarly, in H9C2 cells, knockdown of 
PKCβ2 by siRNA reduced PKCβ2 phosphorylation in cells incubated in normal LG 
and HG conditions (Figure 3D), and attenuated decreased Cav-3 expression in cells 
exposed to HG, with no impact upon Cav-3 expression in cells exposed to normal 
glucose LG (Figure 3E). 
 
Hyperglycemia-induced activation of PKCβ2 is associated with caveolae-
modulated Akt/eNOS signaling 
Next, we investigate the impact of PKCβ2 activation by HG, in the downstream 
signaling molecules Akt and eNOS, both modulated by caveolins(35). 
Cardiomyocytes incubated in HG exhibited decreased phosphorylation of Akt at 
Ser
473 
and eNOS at Ser
1177
, and these decreases were reversed by CGP treatment 
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(Figures 4A and B). Caveolar disruption by CD further exaggerated HG-mediated 
reduction of Akt phosphorylation (Figure 4A), but did not further exacerbate HG-
induced reduction of p-eNOS expression (Figure 4B). However, CGP mediated 
restoration of eNOS phosphorylation in HG-treated cardiomyocytes was abolished 
during concomitant CD treatment (Figure 4B). To confirm the relative effects of 
PKCβ2 and Cav-3 upon HG-mediated changes in p-AKT and p-eNOS, H9C2 cells 
were subject to both PKCβ2 and Cav-3 knockdown by siRNA. PKCβ2 
knockdownsignificantly increased the phosphorylation of Akt and eNOS in HG-
treated cells, effects which were not observed in LG-treated cells (Figure 4C). 
Knockdown of Cav-3 resulted in dramatically further reduced expression of both p-
Akt and p-eNOS in both LG and HG-treated cells (Figure 4D). 
 
Inhibition of PKCβ2 activation by specific pharmacologic inhibitor (LY333531) 
attenuates cardiac caveolar dysfunction in diabetic rats 
To further investigate the role of PKCβ2 activation in diabetes-induced abnormalities, 
we treated STZ-induced diabetic rats with the PKCβ inhibitor LY333531 for 4 weeks. 
PKCβ2, but not PKCβ1, isoform was overexpressed excessively activated in the 
diabetic heart, as demonstrated by increased membrane translocation of PKCβ2 but 
not PKCβ1, a phenomenon inhibited by LY333531 (Figure 5A). PKCβ2-inhibitor 
LY333531 administration suppressed augmented whole-heart Cav-1 expression 
(Figure 5B), and prevented whole-heart decreased Cav-3 expression (Figure 5C). 
Caveolae fractions were isolated via discontinuous sucrose gradient centrifugation of 
whole cell lysates. Cav-1 was found predominantly in fractions 8-10, whereas Cav-3 
was located within both lipid fractions (4-6) and heavier fractions (8-12). PKCβ2 was 
predominantly co-expressed within Cav-3-rich fractions (Figure 5D). Densitometric 
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analysis of all fractions (1-12) demonstrated that PKCβ2-inhibitor LY333531 
significantly reduced augmented Cav-1 and PKCβ2 expression, and suppressed 
decreased Cav-3 expression in diabetes (Figure 5E). 
 
Inhibition of PKCβ2 activation by specific pharmacologic inhibitor (LY333531) 
attenuates diastolic dysfunction in diabetic rats 
At the end of the treatment period, untreated diabetic rats had significantly elevated 
blood glucose and reduced body weight and heart weight as compared to control rats, 
which were not altered by LY333531 treatment (Table 1). However, PKCβ2-inhibitor 
LY333531 reduced the augmented the ratio of heart-weight to body-weight, an 
indirect index of myocardial hypertrophy, in the untreated diabetic rats was 
significantly higher than that in the control rats, which was significantly attenuated by 
LY333531 treatment (Table 1), while exhibiting no effect upon hyperglycemia degree 
(Figure 6B).  Further, the left ventricular cardiomyocyte cross-sectional areas as 
assessed in H&E stained cardiac sections (methodology available at Online appendix) 
in the untreated diabetic rats was significantly bigger than that in the control rats and 
was significantly attenuated by LY333531 treatment (online appendix Figure 1), 
showing that LY333531 can attenuate cardiomyocyte hypertrophy in diabetes. We 
further determined rat cardiac function via echocardiography. As shown in table 1, no 
significant change in fractional shorting (FS), fractional left ventricular posterior wall 
thickening (FLVPW), and ejection fraction (EF) was observed among all 
experimental groups (although non-significant decreased values were recorded in the 
untreated diabetic group, Figure 6C). Such data suggests preserved systolic function 
at 4 5 weeks in diabetic rats as used in our model. However, diastolic dysfunction was 
observed manifested.  The, as both heart rate (HR) and the ratio of peak velocity of 
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early and late diastolic filling (E/A) was significantly decreased in diabetic rats as a 
consequence of significant reduction of E velocity and enhancement of A velocity that 
was concomitant with significant increase in left ventricular (LV) isovolumic 
relaxation time (IVRT) and reductions in LV end-diastolic volume (LVVd) and stroke 
volume (SV). Four weeks treatment with LY333531 restored the values of E/A, IVRT, 
LVVd and SV to levels that were comparable to that in the control rats but without 
significant effect upon HR.  
 
PKCβ2-inhibitor LY333531 ameliorated diabetic-induced derangements of 
myocardial NO, O2
-
 and nitrotyrosine content, and reverted changes in cardiac 
Akt, eNOS and iNOS 
Diabetes is associated with decreased NO levels, and increased O2
- 
and nitrotyrosine 
production(15, 36), agents of oxidative and nitrative stress. To determine whether 
PKCβ2 inhibitor LY333531 conferred cardioprotection in part by reducing oxidative 
and nitrative stress in diabetes, the levels of NO, O2
-
, and nitrotyrosine in diabetic 
heart tissues were assessed. The diabetic condition significantly decreased NO levels 
(Figure 6A) and increased O2
-
 (Figure 6B) and nitrotyrosine production (Figure 6C) in 
cardiac tissues. PKCβ2-inhibitor LY333531 suppressed all these derangements. 
Further studies revealed that the diabetes-induced augmented O2
-
 levels could be 
blocked by the NOS inhibitor L-NAME (100 µM) (Figure 6B), suggesting a NOS-
dependent mechanism for O2
-
 accumulation. We next investigated related signaling 
molecules, including Akt, eNOS, and iNOS. The diabetic condition did not affect total 
cardiac Akt and eNOS expression, but significantly decreased p-Akt (Ser 473) and p-
eNOS (Ser 1177) expression, both reversed by LY333531 (Figures 6D and E). 
Consistent with a recent study (37), our results demonstrated diabetes increased 
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myocardial iNOS (an adverse marker mediating nitrative stress (24)), which was 
reversed by LY333531 (Figure 6F).
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DISCUSSION 
In the present study, we have demonstrated that hyperglycemia-induced cardiac 
PKCβ2 activation requires caveolae. We provided evidence that excessive PKCβ2 
activation is associated with reduced Cav-3 expression, contributing to abnormal 
Akt/eNOS signaling during hyperglycemia. Selective pharmacologic iInhibition of 
excessive activation of PKCβ2 by compound LY333531 improves cardiac diastolic 
function, possibly via attenuation of caveolar dysfunction and rescuing Akt/eNOS/NO 
function in the diabetic heart. To our best knowledge, this is the first study examining 
the relationship between PKCβ2 and Cav-3 in cardiomyocytes subjected to 
hyperglycemic conditions. 
It is well-established that chronic hyperglycemia induces abnormal activation of PKC, 
which contributes to diabetic cardiovascular complications(38, 39). However, the 
PKC signaling pathway is complicated by numerous isoforms, each with varying 
cellular distribution and opposing function at times (40). The PKCβ2 isoform is most 
frequently implicated in diabetic cardiovascular complications (5-8). Our current 
study further confirmed that PKCβ2, but not PKCβ1, is excessively activated in the 
diabetic heart. Although the precise mechanisms by which hyperglycemia induces 
PKCβ2 activation in cardiomyocytes are not fully understood, evidence supports the 
vital role of caveolae (the specialized plasma membrane microdomains modulating 
signaling transduction pathways of molecules docked within them (17)) in 
hyperglycemia-induced PKCβ2 activation. This is well supported by our 
immunoprecipitation and immunofluorescence studies demonstrating hyperglycemia 
increased the association and co-localization of PKCβ2 and Cav-3. Caveolar 
disruption by methyl-β-cyclodextrin(34) suppressed hyperglycemia-induced PKCβ2 
activation in isolated cardiomyocytes. Cav-3 knockdown by siRNA prevented 
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augmented PKCβ2 phosphorylation in H9C2 cells exposed to high-glucose, 
suggesting that Cav-3 is required specifically for hyperglycemia-induced PKCβ2 
activation in cardiomyocytes.  
Cav-3 is the predominant cardiomyocyte caveolin isoform essential for caveolar 
function. In the current study, we demonstrated that cardiomyocyte Cav-3 expression 
increased 6-12 hours after HG exposure but reduced to basal levels within 24 hours 
and progressively further reduced to lower than basal levels after 36 to 48 hours of 
HG exposure. The initial increase in Cav-3 expression after HG exposure observed in 
our study is an acute response to the calorie surplus similar to that reported by other 
researchers(41). The significant reduction of Cav-3 expression in cardiomyocytes 
after prolonged HG exposure is consistent with our results from the intact rats which 
showed that Cav-3 expression was decreased in isolated cardiomyocytes from rats of 
8- and 45-week duration of diabetic condition. Loss of Cav-3 expression results in 
cardiomyopathy(42), and reduction in cardiac Cav3 protein expression is highly 
correlated with reduction in and is associated with left ventricular fractional 
shortening dysfunction in mice with constitutive overexpression of A1-adenosine 
receptor induced cardiac dilatation and dysfunction, and with makers of heart failure 
phenotype in humans in murine heart failure models and in human heart failure (43). 
Our study results suggest excess PKCβ2 activation contributes towards attenuated 
Cav-3 expression in the diabetic heart, as inhibition of PKCβ2 activation by 
CGP53353 or siRNA-mediated PKCβ2 expression knockdown prevented the decline 
of Cav-3 expression in cells exposed to HG. Additionally, pharmacologic inhibition of 
PKCβ2 by LY333531 treatment ameliorated diabetic heart caveolar caveolae 
dysfunction. 
PKCβ2 activation likely exerts adverse effects in the diabetic heart via alteration of the 
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Akt/eNOS signaling pathway, which is modulated by caveolins(35). Although Cav-1 
negatively regulates eNOS in cardiovascular tissues (44, 45), the co-localization of 
Cav-3 and eNOS may facilitate eNOS activation by both cell surface receptors and 
cellular surface NO release for intercellular signaling in cardiomyocytes(18). This is 
supported by our findings that disruption of caveolae function by methyl-β-
cyclodextrin or Cav-3 siRNA prevented Akt phosphorylation and suppressed eNOS 
phosphorylation in cardiomyocytes. Additionally, hyperglycemia decreased 
phosphorylated Akt and eNOS in both isolated cardiomyocytes and in diabetic heart 
tissues, leading to decreased myocardial NO levels, reduced Cav-3 levels, and 
increased Cav-1 cardiac levels. Inhibition of PKCβ2 activation suppressed or 
abrogated these alterations. Therefore, inhibition of PKCβ2 activation may rescue 
proper Akt/eNOS/NO signaling in the diabetic heart via caveolin regulation. 
Previous studies have demonstrated involvement of increased iNOS expression with 
cardiovascular abnormalities in STZ-induced diabetic rats (24, 46). Our study 
confirms increased iNOS cardiac content in diabetic rats, an adverse mediator of 
nitrative stress (24), and increased nitrotyrosine was also demonstrated in diabetic 
heart tissue. The NOS inhibitor L-NAME blocked diabetes-induced augmentation of 
O2
-
 levels, indicating eNOS uncoupling, which is in line with a recent study in STZ-
induced diabetic mice (47). Furthermore, treatment of diabetic rats with PKCβ2 
inhibitor LY333531 inhibited cardiac iNOS expression and reduced both nitrotyrosine 
and O2
-
 production. Diabetes is associated with decreased NO levels and increased O2
-
and nitrotyrosine production (15, 36), which are implicated with oxidative/nitrative 
stress and eNOS uncoupling. Our study provides direct evidence showing that 
inhibition of PKCβ2 activation can mitigate oxidative/nitrative stress and eNOS 
uncoupling. 
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Initial left ventricular diastolic dysfunction, reduced contractility, and prolonged 
diastole are the hallmarks of diabetic cardiomyopathy (48, 49). In the present study, 
echocardiography revealed that diabetes decreased the ratio of peak velocity of early 
and late diastolic filling (E/A) diabetes significantly reduced E/A ratio that was 
concomitant with significantly increased left ventricular isovolumic relaxation time 
(IVRT and decreased LVVd and SV, but did not alter fractional shorting (FS), 
fractional left ventricular posterior wall thickening (FLVPW) or ejection fraction 
(EF). Such data indicates that myocardial diastolic (but not systolic) dysfunction 
occurs in 45-week STZ-induced diabetic rats, which can be ameliorated by PKCβ2 
inhibition with LY333531. -mediated PKCβ2 inhibition–a potentially efficacious 
approach for preserving cardiac function in diabetic cardiomyopathy. Our findings are 
in general agreement with the findings of Mihm MJ et al (27) who conducted a series 
study in a similar STZ-diabetic rats and showed that diastolic dysfunction occurred 
early during the course of the disease which progressed to LV dilation reflected as 
increases in LVIDd and LVIDs with concomitant increase in LV luminal area and 
systolic dysfunction reflected as reduction in LV FS 35 days after STZ-injection and 
onward. It should be noted that the E/A ratio derived from the conventional Doppler 
echocardiography as used in our current study is not a load-independent parameter 
and may have inherent limitations, such as the peak E wave velocity can be highly 
dependent upon heart rate(27), while the heart rate in the diabetic rats was lower than 
that in the control group (Table 1). The newly developed Doppler tissue 
echocardiography (DTE) can acquire myocardial wall and mitral annular velocity 
online and the early diastolic annular velocity measured using DTE has been reported 
to be a preload independent index for evaluating LV diastolic function. A combination 
of DTE derived E’/A’ ratio and the mitral inflow patterns (E/A ratio) obtained by 
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conventional Doppler echocardiography in future studies should help to provide better 
estimations of diastolic dysfunction. However, the significant reduction of E/A ratio 
as a consequence of significant reduction of E velocity and significant enhancement 
of A velocity in combination with concomitant increase in IVRT and reductions in 
LVVD and SV in the diabetic group could jointly suggest diastolic dysfunction in the 
current study. LY333531 treatment in diabetic rats did not affect heart rate but 
corrected all the above changes, suggesting the LY333531 treatment prevented the 
development of diastolic dysfunction. Future functional study with cardiomyocytes 
isolated from various stages of diabetes rodents will help establish the relative 
contribution of the slowing in cardiomyocyte relaxation time and left ventricular 
stiffness (due to fibrosis) to the development of  diastolic dysfunction. 
In summary, our study demonstrates that hyperglycemia-induced PKCβ2 activation is 
associated with caveolar dysfunction, and consequently deranged Akt/eNOS signaling 
(Figure 8 7). Inhibition of PKCβ2 activation attenuated cardiac diastolic dysfunction 
by restoring caveolin-3 expression and subsequently rescuing Akt/eNOS/NO 
signaling. PKCβ2 blockade may therefore represent a novel therapeutic avenue in the 
treatment of diabetic cardiomyopathy.  
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Table 1  
General characteristics and echocardiographic assessment of left ventricle dimensions 
and functions in rats 
 C D D+LY 
Blood glucose（mM） 6.26±0.53 28.24±4.64** 27.32±3.43** 
Body weight (g) 490.1±14.3 295.4±28.8
*
 371.1±17.4
*
 
Heart weight (g) 1.66±0.15 1.25±0.18
*
 1.31±0.16
*
 
Heart weight/bodyweight（mg/g） 3.39±0.07 4.23±0.06* 3.53±0.08# 
HR（bpm） 332±7.8 270±10.8* 286±9.2* 
LVIDs (mm) 4.75±0.43 4.68±0.41 4.74±0.49 
LVIDd (mm) 8.29±0.53 7.61±0.62 8.13±0.49 
FS (%) 42.70±4.13 38.50±5.42 41.53±3.84 
IVSs（mm） 2.23±0.16 2.28±0.07 2.27±0.13 
IVSd (mm) 1.72±0.05 1.75±0.05 1.73±0.06 
LVPWs (mm) 2.90±0.08 2.92±0.07 2.91±0.06 
LVPWd (mm) 1.85±0.06 1.91±0.09 1.87±0.08 
LVPW (%) 56.76±7.50 52.88±10.03 55.61±4.81 
LVVs (µL) 107.6±15.8 109.8±13.7 114.5±11.9 
LVVd (µL) 378.7±25.6 315.4±21.8
*
 380.4±19.7
#
 
EF (%) 71.6±4.7 65.2±5.7 69.9±3.9 
IVRT (ms) 21.75±1.25 27.83±1.80
*
 20.63±1.38
#
 
E Velocity (cm/s) 1340.9±44.6 1217.8±33.7
*
 1331.0±40.8
#
 
A Velocity (cm/s) 890.1±37.1 1023.4±34.7
*
 917.9±28.9
#
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E/A 1.49±0.09 1.19±0.05
*
 1.45±0.085
#
 
SV (µL) 285.7±19.1 230.8±17.9
*
 279.4±20.8
#
 
Control or STZ-induced diabetic rats were either untreated or treated with PKCβ 
inhibitor LY333531 (LY, 1 mg/kg/day) by oral gavage for four weeks. HR, heart rate; 
LV, left ventricle; LVIDs, LV internal systolic diameter; LVIDd, LV internal diastolic 
diameter; FS, fractional shortening; IVSs, systolic interventricular septal thickness; 
IVSd, diastolic interventricular septal thickness; LVPWs, LV systolic posterior wall 
thickness; LVPWd, LV diastolic posterior wall thickness; LVVs, LV end-systolic 
volume; LVVd, LV end-diastolic volume; EF, ejection fraction; IVRT, isovolumetric 
relaxation time; SV, stroke volume. All the results are expressed as means ± S.E.M., n 
= 8, control (C), diabetes (D), LY333531 (LY). 
*
P < 0.05, 
**
P < 0.01 vs. C; 
#
P < 0.05 
vs. D. 
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Titles and legends to figures 
 
Figure 1.Expression of PKCβ2 and Cav-3 in cardiomyocytes isolated from control 
and STZ-induced diabetic rats (8-weeks). (A) Representative Western blot 
demonstrating p-PKCβ2 (Ser 660) and total-PKCβ2 expression. (B) Representative 
Western blot demonstrating Cav-3 expression with GAPDH as loading control. (C) 
Cell lysates containing equal amounts of total protein were subjected to 
immunoprecipitation with anti-Cav-3 antibody, and analyzed by immunoblot with 
PKCβ2 and Cav-3 antibody. All results expressed as means ± S.E.M., n=6-8 per group, 
*
P<0.05 vs. control. (D) Confocal laser microscopic image of adult rat 
cardiomyocytes in response to high glucose. Isolated cardiomyocytes from non-
diabetic rats were incubated with low or high glucose for 36 hours, and underwent 
standard immunofluorescent staining with PKCβ2 and Cav-3 antibodies (see 
Methods). 
 
Figure 2.Effects of high glucose upon p-PKCβ2 (Ser-660) and Cav-3 expression and 
LDH release in cultured cardiomyocytes over time. Representative Western blot of p-
PKCβ2 (Ser 660) expression in comparison with (A) total-PKCβ2 and (B) Cav-3 
expression with GAPDH as loading control. (C) Effects of high glucose upon LDH 
release. 
*
P<0.05 vs. control (time “0”) group. 
 
Figure 3.Expression of p-PKCβ2 and Cav-3 in cultured cardiomyocytes and H9C2 
cells following various treatments in low (5.5 mM) or high (25 mM) glucose 
conditions for 36 hours. (A) Representative Western blot demonstrating p-PKCβ2 (Ser 
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660) in comparison to total-PKCβ2 in cardiomyocytes exposed to high glucose in the 
presence of a selective PKCβ2 inhibitor CGP-53353 (CGP, 1µM) or methyl-β-
cyclodextrin (CD, 10 µM). (B) Representative Western blot demonstrating p-PKCβ2 
and Cav-3 expression in H9C2 cells transfected with Cav-3 siRNA, exposed to low or 
high glucose. (C) Representative Western blot demonstrating Cav-3 expression in 
cultured cardiomyocytes exposed to high glucose in the presence of CGP (1µM). 
Representative Western blot demonstrating (D) p-PKCβ2, total PKCβ2 expression, and 
(D) Cav-3 expression in H9C2 cells transfected with PKCβ2siRNA in low or high 
glucose conditions. GADPH served as loading control. All results are expressed as 
means ± S.E.M., n=7, 
*
P<0.05 vs. all other groups, 
#
P<0.05 vs. control-siRNA treated 
groups. 
 
Figure 4.Expression of p-Akt (Ser 473) and p-eNOS (Ser 1177) in cultured 
cardiomyocytes and H9C2 cells in various treatments in low (5.5 mM) or high 
glucose (25 mM) conditions for 36 hours. (A) Representative Western blot 
demonstrating p-Akt in comparison to total Akt, and (B) p-eNOS in comparison with 
total eNOS in cardiomyocytes exposed to high glucose in the presence of a selective 
PKCβ2 inhibitor CGP-53353 (CGP, 1µM), methyl-β-cyclodextrin (CD, 10 µM), or 
CGP+CD combination. Representative Western blot demonstrating p-Akt and p-
eNOS expression in H9C2 cells transfected with (C) PKCβ2siRNA or (D) Cav-3 
siRNA in low or high glucose conditions. GAPDH served as loading control. All 
results are expressed as means ± S.E.M., n=7, 
*
P<0.05 vs. all other groups, 
#
P<0.05 
vs. control-siRNA treated groups. 
 
Figure 5.Effects of PKCβ inhibitor (LY333531) treatment upon subcellular 
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distributions of PKCβ1 and PKCβ2, and expression levels of Cav-1 and Cav-3 in total 
heart preparations and various isolated cellular fractions. Control (C) or STZ-induced 
diabetic rats were treated with PKCβ inhibitor LY333531 (1 mg/kg/day, D+LY) or 
control (D) by oral gavage for four weeks. (A) Representative Western blot 
demonstrating PKCβ1 and PKCβ2 protein expression. GAPDH and Na-K-ATPase 
served as loading controls in cytosol fractions or membrane fractions respectively. 
(Bottom graph) Membrane:cytosol ratio as indexes of PKCβ isoform translocation. 
Representative Western blot demonstrating (B) Cav-1 and (C) Cav-3 content in total 
heart preparations. (D) Sucrose gradient centrifugation isolated caveolae-enriched 
fractions. Aliquots containing equal amounts of protein or a volume equal to that of 
the fraction with the least detectable amount of protein for “protein-free” fractions (1 
and 2), and unfractionated samples (UF) were probed for Cav-1, Cav-3, and 
PKCβ2immunoreactivity. (E) Cav-1 and Cav-3 and PKCβ2 expression in all the 
fractions (1-12) were calculated by relative densitometric values, and expressed as 
percentage of control. All results expressed as means ± S.E.M., n=7, 
*
P<0.05 vs. all 
other groups. 
 
Figure 6.Effects of PKCβ inhibitor (LY333531) treatment upon general 
characteristics and cardiac function of diabetic rats. Control (C) or STZ-induced 
diabetic rats were treated with PKCβ inhibitor LY333531 (1 mg/kg/day, D+LY) or 
control (D) by oral gavage for four weeks. Effects of LY333531 upon the (A) ratio of 
heart weight to body weight and (B) plasma glucose. (C) Effects of LY333531 upon 
heart rate (HR), fractional shortening (FS), fractional left ventricular posterior wall 
thickening (FLVPW), ejection fraction (EF), left ventricular isovolumic relaxation 
time (IVRT), and the ratio of peak velocity of early and late diastolic filling (E/A). All 
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results expressed as means ± S.E.M., n=7, 
*
P<0.05 vs. all other groups. 
 
Figure 7 6.Effects of PKCβ inhibitor (LY333531) treatment upon the levels of NO, 
O2
-
, nitrotyrosine, and protein expression of p-Akt, p-eNOS, and iNOS in diabetic 
myocardium. Control (C) or STZ-induced diabetic rats were treated with PKCβ 
inhibitor LY333531 (1 mg/kg/day, D+LY) or control (D) by oral gavage for four 
weeks. Effects of LY333531 upon (A) myocardial NO levels, (B) O2
- 
levels in the 
absence and presence of L-NAME, and (C) nitrotyrosine levels; Representative 
Western blot of (D) p-Akt compared to total Akt, (E) p-eNOS compared to total 
eNOS, and (F) iNOS with GAPDH as loading control. All results expressed as means 
± S.E.M., n=7, 
*
P<0.05 vs. all other groups. 
 
Figure 8 7.Schematic depicting hyperglycemia-induced PKCβ2 activation effects 
upon Cav-3-modulated Akt/eNOS signaling pathway.Cardiomyocytecaveolae are 
required for hyperglycemia-induced PKCβ2 activation (translocation from cytosol to 
caveolae membrane). Excessive PKCβ2activation decreased cav-3 expression, 
impairing the Akt/eNOS signaling pathway. Solid arrows depict stimulation, while 
transverse “T” shape indicates inhibition. 
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METHODS  
Mesurement of cardiomyocytes cross-sectional area 
Cardiomyocyte cross-sectional diameters were assessed by H&E (haematoxylin and 
eosin)-stained paraffin-embedded sections of left ventricles (1–2 µm) longitudinally 
orientated to the muscle fibers in the subendocardium and subepicardium. 
Cross-sectional areas were randomly selected in five fields that visualized capillary 
profiles and nuclei. Images of the left ventricle sections were captured by an 
Axisoplus image-capturing system (Zeiss) and analysed by Axiovision Rel.4.5 
image-analysing software. A minimum of 150 cells per animal were chosen for 
analysis. 
RESULTS 
Effects of LY333531 on the left ventricular cardiomyocytes cross-sectional areas 
In order to confirm the morphological abnormality of the left ventricles, the 
cross-sectional areas of cardiomyocyte were used as an indicator of cardiac 
hypertrophy and were assessed in H&E-stained cardiac sections. As shown in Figure 
1, the cross-sectional area in diabetic rats was significantly increased as compared 
with that in the control group, which was significantly attenuated by LY333531 
treatment. 
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Figure 1. Effects of LY333531 treatment on the left ventricular cardiomyocytes 
cross-sectional areas in diabetic rats. The images represent left ventricular 
cardiomyocytes in control (A), diabetes (B) and diabetes with LY333531 treatment 
group (C). (D) Quantification of the cross-sectional areas of cardiomyocytes among 
experimental groups. All results expressed as means ± S.E.M., n=7, 
*
P<0.05 vs. all 
other groups. 
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